- Home
- OLMA vs VRDN Comparison
OLMA vs VRDN Comparison
Compare OLMA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLMA | VRDN |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OLMA | VRDN |
|---|---|---|
| Price | $13.74 | $17.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $44.89 | $35.46 |
| AVG Volume (30 Days) | 785.9K | ★ 2.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | N/A | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.89 | $12.48 |
| 52 Week High | $36.26 | $34.29 |
Technical Indicators
Market Signals| Indicator | OLMA | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 53.41 |
| Support Level | $13.11 | $15.68 |
| Resistance Level | $17.23 | $19.54 |
| Average True Range (ATR) | 0.81 | 0.87 |
| MACD | -0.05 | 0.70 |
| Stochastic Oscillator | 28.41 | 62.90 |
Price Performance
Historical ComparisonAbout OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.